Comparison of initial intraocular pressure response with topical β-adrenergic antagonists and prostaglandin analogues in African American and white individuals in the ocular hypertension treatment study

Archives of Ophthalmology

Volumn 125, Issue 4, 2007, Pages 454-459

  Mansberger, Steven L ^a   Hughes, Bret A ^b   Gordon, Mae O ^c   Spaner, Steven D ^c   Beiser, Julia A ^c   Cioffi, George A ^a   Kass, Michael A ^c  

^a DEVERS EYE INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; CARTEOLOL; LEVOBUNOLOL; METIPRANOLOL; PROSTAGLANDIN DERIVATIVE; TIMOLOL; TIMOLOL MALEATE;

ADULT; AFRICAN AMERICAN; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA THICKNESS; EUROPEAN AMERICAN; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RACE DIFFERENCE; TREATMENT RESPONSE;

ADMINISTRATION, TOPICAL; ADRENERGIC BETA-ANTAGONISTS; ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC; TONOMETRY, OCULAR;

EID: 34247095473     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.125.4.454     Document Type: Article

References (25)

1. Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med. 1991;325:1412-1417.
2. Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma: the Baltimore Eye Survey. JAMA. 1991;266:369-374.
3. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714-720.
4. Sommer A. Glaucoma risk factors observed in the Baltimore Eye Survey. Curr Opin Ophthalmol. 1996;7:93-98.
5. Tielsch JM, Katz J, Singh K, et al. A population-based evaluation of glaucoma screening: the Baltimore Eye Survey. Am J Epidemiol. 1991;134:1102-1110.
6. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713.
7. Higginbotham EJ, Gordon MO, Beiser JA, et al. The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals. Arch Ophthalmol. 2004;122:813-820.
8. Higginbotham EJ, Schuman JS, Goldberg I, et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002;120:1286-1293.
9. Katz IM, Berger ET. Effects of iris pigmentation on response of ocular pressure to timolol. Surv Ophthalmol. 1979;23:395-398.
10. Mundorf TK, Ogawa T, Naka H, Novack GD, Crockett RS. A 12-month, multicenter, randomized, double-masked, parallel-group comparison of timolol-LA once daily and timolol maleate ophthalmic solution twice daily in the treatment of adults with glaucoma or ocular hypertension. Clin Ther. 2004;26:541-551.
11. Netland PA, Robertson SM, Sullivan EK, et al. Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension. Adv Ther. 2003;20:149-163.
12. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472-484.
13. Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688-703.
14. Gordon MO, Kass MA. The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol. 1999;117:573-583.
15. Ocular Hypertension Treatment Study (OHTS) manuals of procedures. https://vrcc.wustl.edu/mop/mop.htm. Accessed February 6, 2007.
16. Brandt JD, Beiser JA, Kass MA, Gordon MO. Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS). Ophthalmology. 2001;108:1779-1788.
17. McDonald CJ, Mazzuca SA, McCabe GP Jr. How much of the placebo "effect" is really statistical regression? Stat Med. 1983;2:417-427.
18. Brandt JD, Beiser JA, Gordon MO, Kass MA. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study. Am J Ophthalmol. 2004;138:717-722.
19. Camras CB, Toris CB, Sjoquist B, et al. Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery. Ophthalmology. 2004;111:2193-2198.
20. Sjoquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002;47(suppl 1):S6-S12.
21. Calissendorff B, Sjoquist B, Hogberg G, Grunge-Lowerud A. Bioavailability in the human eye of a fixed combination of latanoprost and timolol compared to monotherapy. J Ocul Pharmacol Ther. 2002;18:127-131.
22. Harris LS, Galin MA. Effect of ocular pigmentation on hypotensive response to pilocarpine. Am J Ophthalmol. 1971;72:923-925.
23. Hedman K, Larsson LI. The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican open-angle glaucoma or ocular hypertensive patients. Surv Ophthalmol. 2002;47(suppl 1):S77-S89.
24. Imesch PD, Bindley CD, Khademian Z, et al. Melanocytes and iris color: electron microscopic findings. Arch Ophthalmol. 1996;114:443-447.
25. Wilkerson CL, Syed NA, Fisher MR, et al. Melanocytes and iris color: light microscopic findings. Arch Ophthalmol. 1996;114:437-442.